Inhaled budesonide in the treatment of early COVID-19 (STOIC): a phase 2, open-label, randomised controlled trial – The Lancet Respiratory Medicine Commentary: Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19 – The Lancet Respiratory Medicine   Commentary on Twitter NEW Research— Early administration of inhaled budesonide reduced the likelihood of […]

The post Phase 2 RCT: Inhaled budesonide shows promise for the treatment of early COVID-19 appeared first on Links Medicus.